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individuals. The study population was identified through a data warehouse (DENALI), 
which matches with a probabilistic linkage demographic, clinical and economic data 
of different Healthcare Administrative databases. Using DENALI we detected all sub-
jects who were hospitalized for stroke (ICD-9 CM: 430.xx-438.xx) during the period 
2000–2010. The first hospital admission date was used as index date. We estimated 
incidence, mortality and health care costs (hospitalizations, drugs and outpatient 
examinations/visits) per patient-year from the National Health Service’s perspec-
tive. Results: During the study period, around 530,000 subjects (48.3% male) expe-
rienced at least one hospital admission for stroke, corresponding to 5.2 cases on 1,000 
Lombardy inhabitants per year. Subjects had a mean (±SD) age of 74.0 (±13.2) years. 
Ischemic stroke represented the most frequent diagnosis (36.8%) followed by transient 
ischemic attack (TIA, 11.2%) and hemorrhagic stroke (9.0%). The overall mortality rate 
(x100 person-years) was 11.7, with a significant worst survival for hemorrhagic (16.7) 
and ischemic (9.1) diagnosis with respect to TIA (7.8). The average cost during the 
index year was around 6,000€ /patient-year, 10,000€ /patient-year and 20,000€ /patient-
year for TIA, ischemic and hemorrhagic stroke, respectively. For these diagnoses the 
main cost driver was represented by hospitalizations, accounting for 78%, 87% and 
94%. ConClusions: Stroke is a burdensome condition with a high mortality dis-
abilities and costs, indicating the primary importance in monitoring the developing 
of the disease from the NHS’s perspective. Administrative database analysis shows to 
be an efficient tool to accurately estimate the burden of stroke diagnoses.
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objeCtives: Long-term health and economic consequences of diabetes mellitus 
are of significant importance to health policy makers to identify the most effi-
cient interventions for disease managements. However, existing data are mainly 
from simulation models instead of “real-world” data. The objective of this study 
was to longitudinally evaluate the changes of prevalence of diabetic complica-
tions and associated health care cost in a nationally-representative longitudinal 
diabetic cohort. Methods: We used the 2000-2011 Taiwan’s Longitudinal Health 
Insurance Database (LHID) to conduct a population-based, cohort study of 136,372 
type 2 diabetic patients. Diabetic complications of each patient were calculated 
annually after the cohort entry by the adapted Diabetes Complications Severity 
Index (aDCSI) score (sum of diabetic complication with severity levels, range 0-13) 
using diagnostic codes recorded in the LHID. Study subjects were further catego-
rized into six subgroups according to their aDCSI score (0, 1, 2, 3, 4, 5+) at cohort 
entry. Health care utilizations (including outpatient and inpatient visits) as well as 
direct medical costs for the six subgroups were estimated annually using patient-
level data from the LHID. Results: We found the severity of diabetic complications 
increased over time, especially for patients with aDCSI score of 2 and above at cohort 
entry (at 10-years of follow-up: aDCSI= 0 (cohort entry), 2.37; aDCSI= 1; 3.59; aDCSI= 2; 
4.60; aDCSI= 3; 5.14; aDCSI= 4; 5.96). There were significant differences in health 
care utilizations and associated medical costs among patients stratified by aDCSI 
scores (e.g. at 1 year after cohort entry, mean counts of inpatient visits: 0.14 vs. 1.81 
for aDCSI= 0 vs.5+). Relatively high health care utilizations and associated medical 
costs in the first year of cohort entry were observed for patients with aDCSI score 
of 4 and above at cohort entry ConClusions: We provide significant evidence for 
longitudinal changes in diabetic complications and associated health care utiliza-
tion and medical costs among diabetic patients.
PHS32
tHe burDen Of aCute COrOnary SynDrOme fOr tHe brazIlIan 
SuPPlementary HealtH SyStem
Clark OAC 1, Piha T2, Miranda PA2
1Evidências, Campinas, Brazil, 2AstraZeneca, Cotia, São Paulo, Brazil
objeCtives: To estimate the Brazilian supplementary health system costs of acute 
coronary syndrome (ACS), considering direct costs under the private payer perspec-
tive. Methods: Retrospective transactional-level data collection about hospitaliza-
tion costs based on claims data from a private payer perspective. Data were collected 
based on patients´ admission International Code of Disease version 10 (ICD-10) of 
Myocardial Infarction (MI) or unstable angina (UA). Index hospitalization direct costs 
were retrieved from private databases and a one year follow up was performed to 
evaluate rate of readmission and its associated costs. Patients were divided in 4 
main groups based on treatment adopted at index hospitalization: clinical treat-
ment (CT), angioplasty with stent placement (AngSt), Coronary Artery Bypass Graft 
(CABG) and Angioplasty without stent placement (Ang). Results: 2,803 hospitali-
zations were analyzed.Average age was 61 years old and 77% were men. We found 
that 85,44% underwent AngSt, 7,46% CABG, 5,6% Ang and 1,5% CT. Death rates were 
1,63%, 6,22%, 5,73%, 4,76% for AngSt, CABG, Ang and CT respectively. The average 
hospitalization costs for each group was: US$ 17,656 for AngSt, US$ 20,762 for CABG, 
US$ 15,638 for Ang and US$ 9,331 for CT. Readmission after index hospitalization 
were: 7,56%, 1,91%, 5,1% and 21,43% for AngSt, CABG, Ang and CT respectively. And 
the associated cost were US$ 13,986, US$ 12,643, US$13,000 and US$ 12,945 respec-
tively. ConClusions: AngSt is the most common treatment adopted for managing 
ACS with an average cost of US$ 17,656, followed by CABG with an average cost of 
US$ 20,762. ACS has an important economic burden for private payers that can be 
prevented. Mostly important, rehospitalization after an ACS episodemust be avoided 
due its high economic impact.
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two different sources: the unitary cost published by the Mexican Social Security 
Institute (IMSS) and the recovery cost of the General Hospital of Mexico (both with 
2013 costs). Results: The cost of treating hypoglycemic events varies according 
to severity. The main difference between the severities of hypoglycemia was in 
the hospitalization days; in mild hypoglycemia there was no hospitalization, but 
in a severe hypoglycemia it was considered 1.46 (SD±0.77) days in urgency and 
3.77(SD±1.01) days in hospitalization. In the case of the IMSS, the cost of treating a 
hypoglycemic event was US$997.81, US$1,901.78 and US$2,709.4 for mild, moder-
ate and severe hypoglycemia, while for the General Hospital case the costs were 
US$457.69, US$677.88 and US$902.22, respectively. ConClusions: The high cost 
of providing medical care to patients with hypoglycemia and its complications 
represents an economic burden to the Mexican public health care system. Currently, 
effective therapies exist for the treatment of DM2 which have a lower risk of causing 
hypoglycemic events, and consequently greater control of glucose levels. From a 
public health perspective, the use of agents with greater safety and effectiveness in 
the treatment of DM2 could avoid the high costs of treating hypoglycemic events.
PHS28
eStImatIng mOrbIDIty COStS attrIbutable tO breaSt CanCer amOng 
yOunger WOmen ageD 18 tO 44 yearS—unIteD StateS, 2000–2010
Ekwueme DU1, Trogdon J2, Khavjou O3, Guy Jr. G 1, Li C1
1Centers for Disease Control and Prevention, Atlanta, GA, USA, 2University of North Carolina at 
Chapel Hill, Chapel Hill, GA, USA, 3RTI International, Chapel Hill, NC, USA
objeCtives: Although breast cancer occurs primarily among women over age 50 
years, each year more than 10,000 cases are diagnosed among women aged 18-44 
years. To date, no study has specifically quantified the economic burden of breast 
cancer in this age group in the United States. This study is the first to estimate work 
and home productivity losses due to breast cancer among younger women aged 
18-44 years. Methods: We used a two-part regression model and data from the 
2000–2010 National Health Interview Survey to estimate the number of work and 
home productivity days missed due to breast cancer, adjusted for socioeconomic 
characteristics and comorbidities. We compared our estimates for younger women 
with those of older women aged 45-64 years. Results: Per capita, younger women 
with breast cancer had annual losses of $2,293 (95% confidence interval [CI]: $1,069-
$3,518) from missed work and $288 (95% CI: $105-$471) from missed home produc-
tivity. Younger women too sick to work had annual breast cancer-attributable work 
loss costs of $365 per person (95% CI: $208-$522). In total, breast cancer-attributable 
morbidity costs for younger women were $274 million (95% CI: $128-$420 million) 
for work loss among the employed, $46 million (95% CI: $17-$75 million) for home 
productivity, and $10 million (95% CI: $6-$15 million) for work loss among women 
too sick to work. Older women with breast cancer had lower per capita work loss 
costs but higher total morbidity costs. ConClusions: Younger women with breast 
cancer face significant work and home productivity losses. These results underscore 
the importance of continued efforts by the public health community to support the 
unique needs of younger breast cancer survivors and promote prevention efforts 
throughout the lifespan.
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objeCtives: To determine and compare: 1) the incremental total costs (direct and 
indirect) for children (age 3-17 years) with and without ADHD; and 2) differences in 
the incremental direct costs for children with and without ADHD with respect to age 
groups (infants, 0-5; children, 6-11; and adolescents, 12-17 years); while controlling 
for covariates. Methods: The 2011 Medical Expenditure Panel Survey (MEPS) was 
the data source for the study. The sample consists of all children (age 0-17 years) 
with a diagnosis of ADHD (ICD9-code= 314) (Group-I) and without a diagnosis of 
ADHD (Group-II). The incremental total cost of ADHD comprised of direct expendi-
tures (prescribed medications, inpatient, ambulatory, and emergency department 
care), and the indirect costs (parents’ loss of productivity due to absence from school 
by children). A two-part model with logistic regression and a generalized linear 
model was used to estimate the incremental costs of ADHD while controlling for age, 
gender, race, Charlson co-morbidity index, family income, health insurance, usual 
source of care, area, and region. SAS 9.3 and STATA 12.0 were used for statistical 
analyses. Results: 2011 MEPS included 9838 children (age 0-17 years), of whom 
494 (5.02%) children had a diagnosis of ADHD. Group-I was 2.74 times more likely 
(CI= 1.62 to 4.62, p < 0.001) than Group-II to have an expenditure of at least $1, and, 
among children with positive expenditures, Group-I had 33% higher expenditures 
than Group-II (p = 0.001) after controlling for covariates. The incremental direct cost 
of ADHD was higher among adolescents than infants or children [$683 (p= 0.011) vs. 
$494 (p= 0.018) vs. $458 (p = 0.013)], after controlling for covariates. ConClusions: 
Children with ADHD have significantly higher costs than children without ADHD. 
Further research is needed to substantiate the high expenditures associated with 
ADHD.
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objeCtives: Stroke is a sudden loss of brain function due to inadequate blood flow 
with high impact on health status and severe prognosis. The objective of this analy-
sis was to assess incidence, mortality and economic burden of stroke from a large 
population based-study. Methods: Lombardy Region includes around 9.9 million 
